KDM1A and acute myeloid leukemia: demonstrated in mouse models of AML that combination therapy – all-trans retinoic acid (ATRA), which enhances cellular differentiation, in conjunction with tranylcypromine (an LSD1-inhibitor) – decreased tumor burden more substantially than the use of either agent alone (Schenk et al., 2012).